Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
Biocon Q1FY21 Revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr
- Thu, 23-Jul-2020
- Posted by: Biocon Biologics
No Comments
Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins
- Tue, 21-Jul-2020
- Posted by: Biocon Biologics
Biocon Presented Insights into Clinical Study That Enabled DCGI Approval of Itolizumab for COVID-19
- Mon, 13-Jul-2020
- Posted by: Biocon Biologics
Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for Emergency Use in Moderate to Severe COVID-19 Patients
- Sat, 11-Jul-2020
- Posted by: Biocon Biologics
Biocon and Mylan Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)
- Fri, 12-Jun-2020
- Posted by: Biocon Biologics
Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year™ 2020 Award
- Fri, 05-Jun-2020
- Posted by: Biocon Biologics
Biocon’s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi’s Four Device Patents for Lantus® SoloSTAR®
- Mon, 01-Jun-2020
- Posted by: Biocon Biologics
Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb® to Treat Critical COVID-19 Patients
- Wed, 27-May-2020
- Posted by: Biocon Biologics
Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity
- Tue, 19-May-2020
- Posted by: Biocon Biologics
Biocon Earnings Q4FY20 Revenue Up 6% at Rs 1,644 Cr; EBITDA Down 11% at Rs 382 Cr; Net Profit Down 42% at Rs 123 Cr
- Thu, 14-May-2020
- Posted by: Biocon Biologics
